Replies to post #114826 on NanoViricides Inc. (NNVC)

[KMBJN]

I disagree with your assessment of the accuracy of the prediction that "EbolaCide2 may not work because of the shape of the virus" due to "the attachment points" not being effective.

The fact that the EbolaCide glycoprotein has a glycan cap that needs to be removed inside the endosome to attach to the NPC-1 receptor is not related to the prediction of the non-symmetric shape of the virus being a problem. Even if the virus was spherical, the fact that there are glycan caps on the glycoprotein and that the virus causes shedding of soluble glycoprotein (chaff or decoy proteins) are the difficult problems, IMO. My concern about the non-symmetric shape of Ebola was that it might be more difficult for the cides to envelope and destroy the virus once the attachments have been made (viral protein binds to viricide ligand). It didn't have to do with not being able to attach due to the shape of the virus. That part shouldn't matter, IMO.

I maintain that the prediction was not accurate, but neither of us knows how much detail they got in understanding the mechanisms of action / partial efficacy / failure of EbolaCide2 in cell culture testing at USAMRIID.

Best of luck to you in your investments. Time will tell if those that speculate NNVC will fail are correct or if those who speculate NNVC will succeed will be correct. In the mean time, we will all continue to speculate and discuss NNVC pro and con, trying to arrive at the truth.